Clinical significance of microRNA-125b and its contribution to ovarian carcinogenesis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• Muinao T, Deka Boruah HP, Pal M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon. 2019;5:e02826.
   PubMed Web of Science ®Google Scholar
• Elias KM, Guo J, Bast RC Jr. Early Detection of Ovarian Cancer. Hematol Oncol Clin North Am. 2018;32:903–914.
   PubMed Web of Science ®Google Scholar
• Lee JM, Minasian L, Kohn EC. New strategies in ovarian cancer treatment. Cancer. 2019;125(Suppl 24):4623–4629.
   PubMedGoogle Scholar
• Sehouli J, Grabowski JP. Surgery in recurrent ovarian cancer. Cancer. 2019;125:4598–4601.
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Hasegawa K, Nagao S. Landscape of systemic therapy for ovarian cancer in 2019: primary therapy. Cancer. 2019;125:4582–4586.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
   PubMed Web of Science ®Google Scholar
• Hu T, Chong Y, Lu S, et al. miR-339 promotes development of stem cell leukemia/lymphoma syndrome via downregulation of the BCL2L11 and BAX proapoptotic genes. Cancer Res. 2018;78:3522–3531.
   PubMed Web of Science ®Google Scholar
• Yong YX, Yang H, Lian J, et al. Up-regulated microRNA-199b-3p represses the apoptosis of cerebral microvascular endothelial cells in ischemic stroke through down-regulation of MAPK/ERK/EGR1 axis. Cell Cycle. 2019;18:1868–1881.
   PubMed Web of Science ®Google Scholar
• Piasecka D, Braun M, Kordek R, et al. MicroRNAs in regulation of triple-negative breast cancer progression. J Cancer Res Clin Oncol. 2018;144:1401–1411.
   PubMed Web of Science ®Google Scholar
• Hosseinahli N, Aghapour M, Duijf PHG, et al. Treating cancer with microRNA replacement therapy: A literature review. J Cell Physiol. 2018;233:5574–5588.
   PubMed Web of Science ®Google Scholar
• Staicu CE, Predescu DV, Rusu CM, et al. Role of microRNAs as clinical cancer biomarkers for ovarian cancer: a short overview. Cells. 2020;9:pii: E169.
   PubMed Web of Science ®Google Scholar
• Yu Z, Ni F, Chen Y, et al. miR-125b suppresses cell proliferation and metastasis by targeting HAX-1 in esophageal squamous cell carcinoma. Pathol Res Pract. 2019;152792.
   PubMed Web of Science ®Google Scholar
• Liu S, Chen Q, Wang Y. MiR-125b-5p suppresses the bladder cancer progression via targeting HK2 and suppressing PI3K/AKT pathway. Hum Cell. 2020;33:185–194.
   PubMed Web of Science ®Google Scholar
• Jesionek-Kupnicka D, Braun M, Trąbska-Kluch B, et al. MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients. Arch Med Sci. 2019;15:504–512.
   PubMed Web of Science ®Google Scholar
• Ren WW, Li DD, Chen X, et al. MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy. Cell Death Dis. 2018;9:547.
   PubMed Web of Science ®Google Scholar
• Bu Q, You F, Pan G, et al. MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD. Biomed Pharmacother. 2017;88:443–448.
   PubMed Web of Science ®Google Scholar
• Wu JG, Wang JJ, Jiang X, et al. MiR-125b promotes cell migration and invasion by targeting PPP1CA-Rb signal pathways in gastric cancer, resulting in a poor prognosis. Gastric Cancer. 2015;18:729–739.
   PubMed Web of Science ®Google Scholar
• Jayaraj R, Nayagam SG, Kar A, et al. Clinical theragnostic relationship between drug-resistance specific miRNA expressions, chemotherapeutic resistance, and sensitivity in breast cancer: a systematic review and meta-analysis. Cells. 2019;8:E1250.
   PubMed Web of Science ®Google Scholar
• Zhu T, Gao W, Chen X, et al. A pilot study of circulating MicroRNA-125b as a diagnostic and prognostic biomarker for epithelial ovarian cancer. Int J Gynecol Cancer. 2017;27:3–10.
   PubMed Web of Science ®Google Scholar
• Guan Y, Yao H, Zheng Z, et al. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer. 2011;128:2274–2283.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang X, Ma Y, et al. Ascites promotes cell migration through the repression of miR-125b in ovarian cancer. Oncotarget. 2017;8:51008–51015.
   PubMedGoogle Scholar
• Garrett SC, Varney KM, Weber DJ, et al. S100A4, a mediator of metastasis. J Biol Chem. 2006;281:677–680.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hansen B, Klingelhöfer J, Grum-Schwensen B, et al. Functional significance of metastasis-inducing S100A4(Mts1) in tumor-stroma interplay. J Biol Chem. 2004;279:24498–24504.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Zhao Q, Du B, et al. MicroRNA-187 inhibits growth and metastasis of osteosarcoma by downregulating S100A4. Cancer Invest. 2018;36:1–9.
   PubMed Web of Science ®Google Scholar
• Yang D, Du G, Xu A, et al. Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4. Am J Cancer Res. 2017;7:2209–2219.
   PubMed Web of Science ®Google Scholar
• He Z, Yu L, Luo S, et al. miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4. BMC Cancer. 2017;17:140.
   PubMed Web of Science ®Google Scholar
• Arend R, Martinez A, Szul T, et al. Biomarkers in ovarian cancer: to be or not to be. Cancer. 2019;125(Suppl 24):4563–4572.
   PubMedGoogle Scholar
• Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? Dup MicroRNAs Cancer Res. 2016;76:3666–3670.
   PubMed Web of Science ®Google Scholar
• Nelson PT, Baldwin DA, Kloosterman WP, et al. RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA. 2006;12:187–191.
   PubMed Web of Science ®Google Scholar
• Prueitt RL, Yi M, Hudson RS, et al. Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate. 2008;68:1152–1164.
   PubMed Web of Science ®Google Scholar
• Scott GK, Goga A, Bhaumik D, et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2007;282:1479–1486.
   PubMed Web of Science ®Google Scholar
• Nishida N, Mimori K, Fabbri M, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res. 2011;17:2725–2733.
   PubMed Web of Science ®Google Scholar
• Chen Z, Guo X, Sun S, et al. Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses. Bioengineered. 2020;11(1):311–317.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li F, Saha MN, et al. miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma. Clin Cancer Res. 2015;21:2399–2411.
   PubMed Web of Science ®Google Scholar
• Dart DA, Koushyar S, Lanning BE, et al. MiR-221 is specifically elevated in PC3 cells and its deletion reduces adhesion, motility and growth. Anticancer Res. 2019;39:5311–5327.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yan LX, Wu QN, et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011;71:3552–3562.
   PubMed Web of Science ®Google Scholar
• Jin Z, Xu S, Yu H, et al. miR-125b inhibits Connexin43 and promotes glioma growth. Cell Mol Neurobiol. 2013;33:1143–1148.
   PubMed Web of Science ®Google Scholar
• Shahab SW, Matyunina LV, Hill CG, et al. The effects of MicroRNA transfections on global patterns of gene expression in ovarian cancer cells are functionally coordinated. BMC Med Genomics. 2012;5:33.
   PubMed Web of Science ®Google Scholar
• Keirsebilck A, Bonné S, Bruyneel E, et al. E-cadherin and metastasin (mts-1/S100A4) expression levels are inversely regulated in two tumor cell families. Cancer Res. 1998;58:4587–4591.
   PubMed Web of Science ®Google Scholar
• Lv Y, Niu Z, Guo X, et al. S100 calcium binding protein A4 (S100A4, metatasin) as a diagnostic and prognostic biomarker in epithelial ovarian cancer. Br J Biomed Sci. 2018;75(2):88–91.
   PubMed Web of Science ®Google Scholar
• Dou C, Liu Z, Xu M, et al. miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4. Cancer Lett. 2016;381(2):380–390.
   PubMed Web of Science ®Google Scholar
• Zhang K, Yu M, Hao F, et al. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo. Cancer Biomark. 2016;17:281–291.
   PubMed Web of Science ®Google Scholar